Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Nephropathol. 2013 Apr;2(2):114-21. doi: 10.12860/JNP.2013.19. Epub 2013 Apr 1.

The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome.

Author information

  • 1Tokyo Medical and Dental University Graduate School of Health Care Sciences, Tokyo, Japan.
  • 2Department of Molecular Target Medicine Screening, Aichi Medical University School of Medicine, Aichi, Japan.
  • 3Department of Environmental Health, National Institute of Public Health, Saitama, Japan.

Abstract

BACKGROUND:

β2-glycoprotein I (β2GPI)-dependent antiphospholipid antibodies (aPLs) are considered to play a pivotal pathogenic role in antiphospholipid syndrome (APS) by inducing the expression of tissue factor, inflammatory cytokines, and chemokines, most of which are dependent upon the NF-κB pathway. Therefore, the NF-κB is regarded as a promising target for the development of a novel therapeutic strategy. However, progress has been limited owing to the fact that there are no widely-used in vivo models, or highly specific inhibitors.

OBJECTIVE:

This study aimed to test the effects of an NF-κB-specific inhibitor, DHMEQ, in preventing thrombus formation using an original mouse model of APS.

MATERIALS AND METHODS:

Specificity of a monoclonal aPL WB-6 was examined by ELISA. WB-6 was injected into normal BALB/c mice with or without DHMEQ treatment. A pulse laser was radiated to a cutaneous vein in the window of a dorsal skinfold chamber attached to the mouse and thrombus formation was observed and recorded under a microscope.

RESULTS:

WB-6 bound preferentially to the caldiolipin (CL)-β2GPI complex rather than to CL alone, or β2GPI alone. WB-6, but not isotype-matched control antibody, induced a prothrombotic state in the mice by inducing tissue factor expression upon circulating monocytes, resulting in thrombus formation at the site of laser-induced endothelial injury. This diathesis was almost completely ameliorated by DHMEQ treatment.

CONCLUSIONS:

Inhibition of the NF-κB pathway is a promising strategy for the development of a novel treatment for APS.

KEYWORDS:

Antiphospholipid syndrome; NF-kappa B; Thrombosis; Tissue factor

PMID:
24475437
[PubMed]
PMCID:
PMC3891145
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk